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We have previously shown that C1q is expressed on endothelial
cells (ECs) of newly formed decidual tissue. Here we demonstrate
that C1q is deposited in wound-healing skin in the absence of C4
and C3 and that C1q mRNA is locally expressed as revealed by
real-time PCR and in situ hybridization. C1q was found to induce
permeability of the EC monolayer, to stimulate EC proliferation
and migration, and to promote tube formation and sprouting of
new vessels in a rat aortic ring assay. Using a murine model of
wound healing we observed that vessel formation was defective
in C1qa−/− mice and was restored to normal after local application
of C1q. The mean vessel density of wound-healing tissue and the
healed wound area were significantly increased in C1q-treated
rats. On the basis of these results we suggest that C1q may rep-
resent a valuable therapeutic agent that can be used to treat
chronic ulcers or other pathological conditions in which angiogen-
esis is impaired, such as myocardial ischemia.
complement | vasculogenesis | animal models
Angiogenesis is a complex process consisting of the growth ofnew capillaries from preexisting blood vessels and is critical
for supplying nutrients, oxygen, and defense factors to newly
formed tissues. Endothelial and mural cells are key players in
this phenomenon, which starts with the disruption of the vas-
culature followed by migration and proliferation of endothelial
cells (ECs) and ends with the organization of a network of tube-
like structures that eventually become new blood vessels (1–3).
The process is very active during embryonic development, con-
tributing to organ growth, but it becomes relatively quiescent in
the postnatal period, except for certain conditions such as for-
mation of maternal decidua in pregnant women, tumor growth,
inflammatory processes, and tissue repair (4).
In physiologic conditions such as wound healing, the angio-
genic process proceeds in an orderly fashion under a balanced
control of proangiogenic and antiangiogenic factors. Conversely,
in pathologic conditions such as malignant tumor growth, rheu-
matoid synovitis, and several other disorders, the persistence of
stimuli can tilt the balance toward sustained angiogenesis, result-
ing in excessive formation of blood vessels. Other diseases in-
cluding ischemic heart disease, preeclampsia, and chronic ulcer
are characterized by reduced angiogenesis that prevents revas-
cularization and tissue regeneration (4).
Several angiogenic factors promote angiogenesis acting on
different vascular cells. VEGF plays a pivotal role in the initia-
tion and progression of blood vessel formation (5, 6) with the
contribution of platelet-derived growth factor, transforming growth
factor-β, fibroblast growth factor, and angiopoietins (7, 8). The
complement (C) system has been shown to establish multiple in-
teractions with the endothelium of blood vessels, leading to ex-
pression of adhesion molecules, leukocyte mobilization, secretion
of proinflammatory cytokines and chemokines, and increased
vascular permeability (9). The finding of C3a, C5a, and mem-
brane attack complex (MAC) deposited in drusen in patients
with age-related macular degeneration raised the possibility that
C may play an important role in the development of choroidal
neovascularisation (CNV), a typical feature of this disease (10,
11). Failure of C3- and C5-deficient mice to develop laser-induced
CNV supports the hypothesis that C contributes to angiogenesis
(12, 13). Consistent with this, the degree of CNV is decreased in
C3aR- and C5aR-deficient mice or in animals treated with C3aR
and C5aR antagonists (11) or with recombinant CD59a-Fc, which
prevents the assembly of MAC (14). However, Langer et al. (15)
have recently reported an inhibitory role of C on angiogenesis in
a mouse model of retinopathy of prematurity. They observed a
defective neovascularization in WT animals compared with C3-
and C5aR-deficient mice and found that C5a was responsible for
the inhibition of angiogenesis by stimulating macrophages to se-
crete the antiangiogenic soluble VEGF receptor-1. Importantly,
all these conflicting reports on the effects of the C system on
angiogenesis depend on C activation and are associated with an
inflammatory process.
Herein we report an alternative way by which the C system can
promote angiogenesis through the action of C1q via an activation-
independent mechanism. C1q is well known to activate the classical
pathway and to act as a defense molecule favoring the removal of
infectious agents, apoptotic cells, and immune complexes (16). In
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recent years, a wealth of data has been collected indicating that C1q
can modulate the function of different cells of both innate and
adaptive immunity (17). For example, C1q can target ECs by
binding to the receptors for the collagen-like tail (cC1qR) and the
globular head of the molecule (gC1qR) as well as to other ligands
such as heparan sulfate. As a result of these interactions, C1q in-
duces adhesion and spreading of ECs and stimulates expression of
adhesion molecules (18) and release of the chemotactic factors IL-8
and monocyte chemoattractant protein-1 and IL-6 (19). C1q has
also been reported to recognize apoptotic ECs (20) and to stimulate
expression of genes in neurons that are associated with neuro-
protection-enhancing neurite outgrowth and limiting neuronal
stress and inflammation (21).
In this paper we will present in vitro and in vivo data dem-
onstrating that C1q exerts a proangiogenic effect and may be
used as a unique therapeutic tool to induce vessel formation in
wound healing.
Results
In Vivo Localization of C1q on Newly Formed Vessels in Granulation
Tissue.Our previous findings that C1q is deposited on the ECs of
vessels in maternal decidua but is absent in other vascular dis-
tricts (22) raised the question of whether C1q may be associated
with newly formed vessels. To this end, we examined the pres-
ence and distribution of C1q in wound healing, a tissue charac-
terized by active angiogenesis. Immunohistochemical analysis
showed that C1q was deposited in the lesional area but was
undetectable in the derma of intact skin (Fig. 1 A and B). The
protein was mainly localized on the vessel endothelium, in the
surrounding stroma, and in scattered inflammatory cells. To as-
sess the ability of C1q to activate the C system through the
classical pathway, the granulation tissue was examined for the
presence and distribution of C1r and C1s using specific anti-
bodies (Fig. S1). Unlike C1q, C1r was absent on endothelium
and was only detected in tissue-infiltrating cells with hystiocytic
morphology (Fig. 1C). C1s showed a distribution similar to that
of C1q and were mainly observed in infiltrating inflammatory
cells and vessels (Fig. 1D), whereas both C4 and C3 were un-
detectable (Fig. 1 E and F).
To investigate the source of C1q, we analyzed wound-healing
tissue for the expression of mRNA for the three chains of C1q by
quantitative RT-PCR and the results were compared with those
obtained with intact skin. As shown in Fig. 2A, the expression
level of the three mRNAs in granulation tissue was significantly
higher than that in normal skin. In situ hybridization revealed the
presence of mRNA for the C chain of C1q in stromal cells and
vascular endothelium of the lesional area, whereas it was un-
detectable in the cells of intact skin (Fig. 2 B–E). We have in-
vestigated specifically the C1qC mRNA expression because we
have previously shown that ECs isolated from normal skin ex-
press only the mRNA for A and B chains of C1q (22).
C1q Induces an Angiogenic Phenotype in Cultured ECs. The detection
of C1q on endothelium and other cells of a tissue characterized by
active angiogenesis led us to examine the role of C1q in angiogen-
esis, analyzing its contribution to vascular permeability, proliferation,
and migration of ECs.
The concentration of C1q used in all experiments (10 μg/mL)
was selected as the maximal amount that binds to ECs in a dose–
response curve (Fig. S2). The endothelial permeability induced by
C1q was evaluated measuring the amount of fluorescein-labeled
BSA leaked through a monolayer of ECs and using bradykinin as
Fig. 1. Immunohistochemical analysis of human dermal granulation tissue
and intact skin. Complement deposition was analyzed using polyclonal
antibodies to various complement components and revealed by the strep-
tavidin–biotin–peroxidase complex method using aminoethyl carbazole as
chromogenic substrate (red signal). Note the localization of C1q on the
endothelium and stroma of the granulation tissue (A), whereas C1q was
undetectable in intact skin (B). Note also that C1r is present only in tissue-
infiltrating cells with histiocytic morphology (C), whereas C1s distribution
resembles that of C1q and is expressed on vessels and infiltrating in-
flammatory cells (D). Both C4 (E) and C3 (F) were undetectable. Arrows in-
dicate blood vessels. (Scale bars, 30 μm.)
Fig. 2. Local expression of C1q mRNA in granula-
tion tissue of wound-healing and intact skin. (A)
Quantitative PCR analysis of RNA extracted from
wound-healing and intact skin. The relative amount
of the three chains of C1q was normalized with 18S
expression and RNA extracted from blood-derived
macrophages was used as calibrator. Data are pre-
sented as mean of three independent experiments ±
SD; *P < 0.05, **P < 0.01 vs. intact skin. (B–E) In situ
hybridization of wound-healing (B and C) and intact
skin (D and E) sections for the C1q C chain mRNA
expression using digoxigenin-labeled antisense (B and
D) and sense (C and E) RNA probes followed by incubation with alkaline phosphatase-conjugated antidigoxigenin antibody and staining with Nitro blue tetra-
zolium and 5-Bromo-4-chloro 3-indolyl phosphate. Arrows indicate blood vessels. (Scale bars, 30 μm.)
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a positive control. As shown in Fig. 3A, C1q exerted a significant
permeabilizing effect on ECs.
C1q was also tested in a proliferation assay incubating ECs
with C1q for different time intervals followed by single-cell
analysis of expression of the proliferation marker Ki-67. The
data presented in Fig. 3B show that the percentage of ECs ex-
pressing Ki-67 increased in the presence of C1q to almost double
that of the control.
The effect of C1q on cell migration was analyzed using a scratch
assay and monitoring the mobilization of ECs toward the
scratched area for 24 h. As shown in Fig. 3C, ECs stimulated by
C1q started to enter the scratched area by 12 h and migrated
farther than cells exposed to medium alone after 24 h. The
promigratory activity of C1q on ECs was also investigated using
a Transwell model system with the membrane insert covered with
fibronectin. ECs were added to the upper chamber and the
number of cells that migrated into the lower chamber containing
either C1q or VEGF or medium was counted at different time
intervals. The results of a dose–response curve established with
increasing amounts of C1q showed a promigratory effect of this C
component that peaked at 5 μg/mL and plateaued thereafter (Fig.
S3). C1q used at a concentration of 10 μg/mL to allow its maximal
binding to ECs stimulated migration of ∼30% of the cells after 2 h
and mobilized more than 70% of the cells at 12 h (Fig. 3D). In this
as well as in all previous assays, VEGF was used as a positive
control and the combination of the two molecules induced mi-
gration of a higher number of cells than each of them tested
separately, suggesting an additive effect (Fig. S4). The possibility
that endotoxin contaminating C1q was responsible for its biologic
effects on cell migration was excluded by boiling C1q for 10 min,
a process that destroys C1q but not LPS, and by blocking LPS with
polymyxin B (50 μg/mL) (Fig. 3E). To identify the portion of C1q
molecule responsible for the promigratory effect, the globular
head (gC1q) and the collagen tail (cC1q) of C1q were examined
separately in the assay and the activity was found to reside mainly
in gC1q (Fig. 3E). The major contribution of gC1q was also sup-
ported by the neutralizing effect of a specific antibody against
gC1qR, whereas an antibody against cC1qR did not exert a sta-
tistically significant inhibition (Fig. 3E). The biologic effect of the
commercial C1q was confirmed using our own preparation of C1q
that was found to be equally active at similar concentration.
To investigate the ability of C1q to activate signaling mole-
cules in human umbilical vein endothelial cells (HUVECs), cell
monolayers were incubated with C1q (10 μg/mL) or VEGF
(20 ng/mL), used as a positive control, for different lengths of
time at 37 °C, and the phosphorylation status of ERK1/2 on total
cell lysates was evaluated by immunoblotting. As shown in Fig.
S5, C1q stimulated the activation of ERK1/2, which was clearly
evident at 15 min and decreased to the baseline at 30 min. In
contrast, the activation induced by VEGF persisted up to 60 min.
Analysis of C1q- and VEGF-mediated activation of p38 revealed
a similar but slightly delayed kinetic expression pattern com-
pared with that of ERK1/2, although the effect of C1q did not
reach statistical significance.
In Vitro and ex Vivo Proangiogenic Effect of C1q.Having established
that C1q stimulates EC proliferation and migration, we next
evaluated the ability of C1q to induce vessel formation using two
different experimental approaches. First, C1q was tested in the in
vitro tube formation assay, growing ECs in Matrigel and staining
the cells for actin to visualize tube formation. The cells incubated
in medium tended to cluster together, forming large aggregates in
the absence of tubular organization. Conversely, C1q induced
marked changes in the cell pattern, with the formation of tubules
assembled by elongation and joining of ECs, and a similar pattern
was observed with VEGF (Fig. 4A). Quantitative analysis of the
data showed that the effect of C1q was clearly seen at 10 h and
became more evident after 24 h of incubation (Fig. 4B).
The ex vivo model of rat aortic ring assay was used as a second
approach to analyze the effect of C1q on vessel sprouting from
Fig. 3. In vitro effects of C1q on endothelial cells.
(A) The permeabilizing activity of C1q (10 μg /mL),
VEGF (20 ng/mL), or bradikinin (BK, 10−6 M) added
to the upper chamber of the Transwell was evalu-
ated measuring the amount of FITC-labeled BSA
leaked through a monolayer of endothelial cells
into the lower chamber. (B) Proliferation of endo-
thelial cells was investigated counting the number
of cells expressing the proliferation marker Ki-67 at
various time intervals after addition of C1q (10
μg/mL) or VEGF (20 ng/mL). (C) Migration of endo-
thelial cells using the scratch assay. A confluent
monolayer of HUVEC was stripped in the middle
with a pipette tip and the scratched area covered by
cells that had migrated after exposure to C1q
(10 μg/mL) or VEGF (20 ng/mL) or medium alone up
to 24 h was measured. The continuous line in the
scratched area represents the limit of cell migration.
The dotted line indicates the border of the scratched
area. (D and E) Migration of endothelial cells from the
upper to the lower chamber of a Transwell system.
C1q (10 μg/mL), VEGF (20 ng/mL), cC1q (0.5 μg/mL), or
gC1q (0.5 μg/mL) was added to the lower chamber
and serum-free medium was used as a control. Boiled
C1q and C1q mixed with polymyxin B (50 μg/mL) were
also analyzed to exclude the presence of LPS. Inhi-
bition experiments were performed incubating the
cells with F(ab)2 anti-cC1qR or anti-gC1qR (40 μg/mL)
for 30 min at 37 °C before addition of C1q. The cells
were allowed to migrate up to 12 h. The data are
expressed as mean of five independent experiments
run in triplicate ± SD; *P < 0.05, **P < 0.01 vs. control.









aortic rings. As shown in Fig. 4C, C1q stimulated microvessel
formation, which was already visible after 6 d of incubation and
became more apparent after 9 d. Because apposition of mural
cells around ECs is required for the assembly of newly formed
vessel, the microvessel sprouting from the aortic ring was exam-
ined by confocal microscopy and found to be made up of a con-
tinuous layer of ECs (green) surrounded by pericytes (red) (Fig.
4D). Quantitative analysis of the proangiogenic activity of C1q
showed that the number of vessels induced by C1q, their maxi-
mal length, and the number of branchings were significantly in-
creased compared with the control values (Fig. 4E).
In Vivo Proangiogenic Activity. The data collected using in vitro
and ex vitro models suggested that C1q has the features of an
angiogenic factor but did not clarify whether it also exhibits an-
giogenic activity in vivo. To address this issue, an animal model of
wound healing was established using WT and C1qa−/− mice. The
animals were killed 14 d after surgery and skin samples were
collected and analyzed for the presence of blood vessels. As shown
in Fig. 5A, a limited number of small vessels was observed in the
wound healing of C1q-deficient animals, in contrast to the overt
angiogenesis observed in WT and C3−/− animals. Interestingly,
local application of C1q to the wound of C1qa−/− mice restored
vessel formation to the level found in WT mice. Evaluation of
mean vascular density (MVD) in wound healing confirmed the
visual observation of tissue sections. In particular, MVD values
were found to be significantly lower in C1qa−/− mice compared
with both C3−/− and WT animals and increased to levels compa-
rable to those observed in C-sufficient mice following treatment of
C1q-deficient animals with C1q (Fig. 5B). The increased number
of vascular vessels induced by C1q was associated with a signifi-
cantly enhanced healing of wounds compared with untreated
wounds (Fig. 5C).
To investigate the potential therapeutic use of C1q as an an-
giogenic factor, the effect of topical application of C1q was
evaluated in a rat model of wound healing. Full-thickness round
wounds were produced on the dorsum of rats and treated with
either C1q or VEGF or saline as positive and negative controls,
respectively. After 14 d the animals were killed and the skin
samples were analyzed for the presence of microvessels. Several
small vessels were observed in both VEGF- and C1q-treated skin
with an MVD value significantly higher than that of the saline
control (Fig. 6 A and B). The animals receiving C1q showed also
a significant increase in the healed wound area, although less
marked than the growing number of blood vessels obtained with
C1q or VEGF (Fig. 6C).
To further explore the mechanism of the angiogenic activity of
C1q, we evaluated the tissue expression of gC1qR using an an-
tibody against this receptor that was found to effectively inhibit
C1q-mediated migration of ECs in the initial in vitro experi-
ments. Fig. S6 shows vessels stained for gC1qR in a tissue section
of wound healing whereas the surrounding intact skin revealed
negligible expression of gC1qR.
Discussion
Understanding the mechanisms by which angiogenesis is regulated
in pathophysiologic conditions is critical to devise successful strat-
egies to control this process in various diseases characterized by
abnormal vessel formation. C has been implicated in the regulation
of angiogenesis, with the main contribution of the activation prod-
ucts of the late components found to exert both a proangiogenic
and antiangiogenic effect in models of choroidal neovascularisation
and retinopathy of prematurity, respectively. The data provided in
this study support a definite role for C1q in promoting angiogenesis
by a direct effect on ECs.
Skin wound healing provided an invaluable tool to investigate
the contribution of C1q to new vessel formation in tissues
characterized by active angiogenesis. This analysis was prompted
by our previous finding that C1q is deposited on ECs of decidua,
serving the important function of promoting adhesion of endo-
vascular trophoblasts and their migration through the inter-
endothelial cell junctions of spiral arteries to partially replace
ECs (22). Because decidua is a newly formed tissue at an embryo
implantation site, we hypothesized that cell-bound C1q may also
play a role in promoting angiogenesis in other situations. The
detection of C1q on ECs of the lesional areas in wound healing
and its absence from the dermal endothelium of intact skin are in
line with our working hypothesis. Although C1s showed a distri-
bution similar to that of C1q in granulation tissue, failure to
reveal colocalization of C1r and C1q and to detect C4 and C3 on
Fig. 4. In vitro and ex vivo angiogenesis induced by
C1q. (A) Capillary-like tubules were allowed to form
from endothelial cells exposed to C1q (10 μg/mL) or
VEGF (20 ng/mL) in Matrigel. The tubules were vi-
sualized after staining with Phalloidin–Alexa Fluor
546. (Scale bars, 300 μm.) (B) Vessel number was
counted using LAS software connected to Leica
microscope. (C) Photomicrographs showing vessel
sproutings formed after 6 and 9 d of incubation of
aortic rings with C1q (10 μg/mL) or VEGF (20 ng/mL).
(Scale bars, 500 μm.) (D) Photomicrograph at two
magnifications (40× and 100×) of a microvessel sprout
(indicated by the rectangular area in C) formed after
9 d of incubation with C1q showing endothelial cells
stained in green with isolectin-B4 and pericytes
stained in red with rabbit IgG anti-NG2. (E) Quantifi-
cation of number and maximal length (millimeters) of
vessels and number of branchings formed after in-
cubation of aortic rings with C1q for 9 d. The data are
expressed as mean of five independent experiments
run in duplicate ± SD; *P < 0.05, **P < 0.01 vs. control.
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the endothelium suggests that the expression of C1q in the
granulation tissue was not associated with complement activa-
tion through the classical pathway despite extensive tissue
remodeling and inflammation. This is not surprising, because
a similar situation is encountered in the decidua that is also char-
acterized by remodeling and active angiogenesis and by endothelial
C1q deposition in the absence of C4 and C3. Plasma is a possible
source of C1q interacting with the membrane of ECs on lesional
areas. However, the involvement of circulating C1q, although po-
tentially possible, is unlikely because binding of plasma C1q to
target cells usually leads to complement activation through the
classical pathway, which apparently does not occur in wound
healing, as suggested by the lack of C4 and C3 deposition and the in
vivo findings with the C3-deficient mice. An alternative possibility
supported by the in situ hybridization data is that C1q is produced
by ECs and interacts with specific receptors and other binding sites
on the cell surface, as already shown for decidual ECs (22).
C1q is one of the most pleiotropic components of the C system
and can elicit a wide variety of biologic activities in different cells
of both innate and acquired immunity. The data presented in this
paper reveal a yet-unrecognized function of C1q to promote
angiogenesis acting on ECs as primary target. C1q exhibits all of
the features of an angiogenic factor inasmuch as it induces an in-
crease in vascular leakage as a result of loosening of interendo-
thelial cell junctions and stimulates cell proliferation and migration.
The increase in EC permeability induced by C1q and VEGF (23)
allows the extravasation of plasma proteins and formation of ex-
tracellular matrix favorable to endothelial and stromal cell migra-
tion (24). C1q also shares with VEGF the ability to induce the
formation of vascular structure evaluated using both the in vitro
Matrigel assay and the ex vivo aortic ring assay.
The C system has been implicated in the promotion of angio-
genesis in laser-induced CNV through C5a and MAC, which pri-
marily stimulate the retinal pigment epithelium to release VEGF
and other angiogenic factors (11, 12). A direct stimulating effect of
C5a on the proliferation and migration of ECs and on their ability
to form ring-shaped structures has more recently been reported by
Kurihara et al. (25). However, the in vivo relevance of this ob-
servation is unclear because Langer et al. (15) provided compel-
ling evidence that C5a exerts an antiangiogenic effect in a murine
model of retinopathy of prematurity, extending previous findings
that C5a triggers the release of antiangiogenic factors associated
with placental dysfunction and poor pregnancy outcomes (26).
As an angiogenic factor, C1q differs significantly from other
components or activation products of the C system for several
reasons. First, its action is independent of C activation and seems
to be related to a direct stimulating effect on ECs. This con-
clusion is supported by the finding that the vessel density in the
wound healing of C3-deficient mice is not different from that
observed in WT animals. Second, the selective expression in skin
undergoing wound healing, but not in intact skin, as revealed by
in situ hybridization, is compatible with a physiologic role played
by locally released C1q in vessel formation of regenerating
Fig. 5. Angiogenesis in a wound-healing model in C1qa−/− and WT mice.
Sections of paraffin-embedded skin of wound-healing samples were ob-
tained from WT, C3−/−, C1qa−/−, and C1qa−/− mice treated with a topical
application of C1q (5 μg) 14 d after surgery and stained for the expression of
CD34. Three animals for each group were used. The MVD was quantified on
five different 200× microscopic fields of skin sections immunostained for
CD34. (A) Representative pictures of CD34 immunostained sections showing
the MVD in WT, C3−/−, C1qa−/−, and C1qa−/− mice treated with C1q. Arrows
indicate blood vessels present in the tissue. (Scale bars, 30 μm.) (B) Quanti-
fication of MVD in five fields of skin sections from WT, C3−/−, C1qa−/−, and
C1q-treated C1qa−/− mice. (C) Evaluation of wound closure expressed as per-
centage of the initial punch biopsy area. The data are presented as mean ± SD;
*P < 0.05 vs. C1qa−/−.
Fig. 6. Angiogenesis in a rat wound-healing model.
(A) Representative pictures of paraffin-embedded skin
sections of wounds treated with local application of
either C1q (5 μg) or VEGF (1 ng) or saline 14 d after
surgery. The sections were stained with anti-CD34.
Arrows indicate blood vessels present in the tissue
(Scale bars, 30 μm.) (B) Sections obtained from five rats
were also analyzed blindly for MVD in five different
fields at 200× magnification. (C) Evaluation of wound
closure expressed as percentage of the initial punch
biopsy area. The data are presented as mean ± SD;
*P < 0.05, **P < 0.01 vs. saline.









tissues. Finally, the finding that angiogenesis is impaired in the
wound bed of C1qa−/− mice and can be rescued to levels similar
to those of WT mice following topical application of purified
C1q further supports its important contribution to the angiogenic
process during wound healing.
The observation that C1q is very effective in inducing new vessel
formation in wound healing both in C1qa−/− mice and in WT rats
raises the issue of the therapeutic use of C1q to promote this process
in pathologic conditions characterized by slow or impaired angio-
genesis. Chronic wounds associated with burns, venous and arterial
insufficiency, diabetes, and peripheral neuropathy are potential
indications for topical administration of C1q. Because the globular
head of C1q interacting with gC1qR seems to be implicated in the
proangiogenic effect of C1q, the fact that gC1qRexpression ismainly
restricted to the skin ulcer and negligible in normal tissue may fa-
cilitate the local therapeutic effect of C1q. This prevalent expression
in wound healing would avoid undesired effects thatmay derive from
stimulation of angiogenesis in normal skin as a result of repeated
administrationswhen the receptor is constitutively expressed, as is the
case of VEGF receptor. Data from Lee et al. (27) suggest that un-
controlled expression of VEGF may lead to the formation of disor-
ganized vessels and hemangiomas.
In conclusion, this study provides evidence indicating that C1q
is selectively localized on the vessel endothelium and in the
stroma of wound healing in the absence of C4 and C3 and acts as
a unique angiogenic factor. Based on these findings, we suggest
that C1q is involved in new vessel formation in tissues un-
dergoing regeneration and may be used as a therapeutic tool to
promote angiogenesis in chronic wound healing and also in
ischemic conditions.
Materials and Methods
Detailed information on materials and methods used in this study is provided
in SI Materials and Methods.
Human Tissue. Dermal granulation tissue and skin biopsy specimens obtained
from patients with skin ulcers were examined for immunohistochemical
analysis, quantitative real-time PCR and in situ hybridization. The primers
used for qPCR and in situ hybridization are reported in Table S1.
Animals. WT mice and rats were purchased from Harlan Laboratories, and
C1qa−/− mice were generated by M.B. and used for the in vivo model of
wound healing.
Reagents. A full list of antibodies and chemicals is provided in detail in SI
Materials and Methods.
Angiogenic Assays. In vitro tests include cell proliferation and migration, EC
permeability, tube formation, and rat aortic ring assay. Wound healing in
mice and rats was used as an in vivo model of angiogenesis.
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